Neurocrine Q1 Revenue Surges 42% to $814.5M, Bolstered by Soleno Acquisition
Summary
Neurocrine Biosciences reported robust first-quarter 2026 results, with total revenues climbing 42% year-over-year to $814.5 million and net product sales reaching $811.0 million, a 44% increase. GAAP diluted EPS for the quarter was $1.91. This strong performance, detailed in an 8-K filing today, indicates continued commercial momentum following the company's 2025 results. The company also reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7–2.8 billion, signaling confidence in its core product. A significant development is the definitive agreement to acquire Soleno Therapeutics, which will add VYKAT XR for Prader-Willi syndrome to Neurocrine's pipeline, representing a strategic expansion. Traders will be watching the successful integration of Soleno Therapeutics and the continued growth trajectory of INGREZZA and CRENESSITY.
At the time of this announcement, NBIX was trading at $143.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $108.35 to $160.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.